What's Happening?
Novo Nordisk has decided to prematurely end two Phase III clinical trials, HERMES (NCT05636176) and ATHENA (NCT06200207), for its inflammation-targeting drug candidate, ziltivekimab. The decision was made following a recommendation from a data monitoring
committee, which concluded that the drug was unlikely to meet its primary goals in either study. Both trials were evaluating ziltivekimab against a placebo in patients suffering from heart failure and inflammation. The HERMES trial aimed to assess the drug's impact on the time to the first occurrence of heart failure endpoints, such as cardiovascular death and heart failure-linked hospitalizations or urgent visits. The ATHENA study focused on ziltivekimab's potential to influence various heart failure-specific factors, including quality of life. This setback follows the failure of the Phase III ZEUS trial (NCT05021835) in July, where ziltivekimab did not reduce the risk of major adverse cardiovascular events (MACE) in patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and inflammation.
Why It's Important?
This termination represents a significant setback for Novo Nordisk's cardiovascular and inflammation drug development pipeline, particularly for ziltivekimab, which was acquired through a $725 million upfront takeover of Corvidia Therapeutics in 2020. The failure of multiple late-stage trials indicates challenges in translating promising early-stage research into effective treatments for complex conditions like heart failure and inflammation. For patients with these conditions, the news means a delay in potential new therapeutic options, as ziltivekimab was hoped to offer a novel approach by targeting IL-6. The substantial investment by Novo Nordisk into this candidate, now facing significant hurdles, could impact future research and development strategies within the pharmaceutical industry, potentially leading to a re-evaluation of similar inflammation-targeting mechanisms for cardiovascular diseases. This outcome also highlights the inherent risks and high costs associated with drug development, even for compounds that show initial promise.
What's Next?
Despite the termination of the HERMES and ATHENA trials, Novo Nordisk plans to continue the Phase III ARTEMIS trial as scheduled. This ongoing study is evaluating ziltivekimab's potential as an acute treatment in the post-heart attack setting, with data readout anticipated in the first half of 2027. All patients enrolled in the terminated HERMES and ATHENA studies will be followed through to their three-month follow-up visit as originally planned. The company will likely analyze the comprehensive data from all three Phase III trials (ZEUS, HERMES, and ATHENA) to understand the reasons behind the drug's lack of efficacy in these specific indications. This analysis will inform future research directions for ziltivekimab, if any, and potentially influence the development of other IL-6-targeting therapies. The outcome of the ARTEMIS trial will be critical in determining the future viability of ziltivekimab as a therapeutic agent.
Beyond the Headlines
The repeated setbacks for ziltivekimab underscore the intricate challenges in developing treatments for multifactorial diseases like heart failure and cardiovascular inflammation. The IL-6 pathway, while implicated in inflammation, may have more complex interactions within the broader physiological context of these diseases than initially understood. This situation could prompt a deeper re-evaluation of the role of specific inflammatory markers in cardiovascular disease progression and treatment. It also highlights the increasing difficulty and cost of bringing new drugs to market, especially in areas with existing treatment options. The pharmaceutical industry may shift focus towards more personalized medicine approaches or combination therapies, rather than single-target interventions, to address the heterogeneity of patient responses. Furthermore, the termination of these trials could lead to increased scrutiny of early-stage acquisition decisions and the due diligence processes involved in high-value biotech buyouts.
